miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling.
Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis that leads to peripheral cytopenias. We observed that SMAD7, a negative regulator of transforming growth factor-beta (TGF-β) receptor-I kinase, is markedly reduced in MDS and leads to ineffective hematopoiesis by overacti...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Conference item |
| Published: |
American Society of Hematology
2013
|
| _version_ | 1826303525634703360 |
|---|---|
| author | Bhagat, T Zhou, L Sokol, L Kessel, R Caceres, G Gundabolu, K Tamari, R Gordon, S Mantzaris, I Jodlowski, T Yu, Y Jing, X Polineni, R Bhatia, K Pellagatti, A Boultwood, J Kambhampati, S Steidl, U Stein, C Ju, W Liu, G Kenny, P List, A Bitzer, M Verma, A |
| author_facet | Bhagat, T Zhou, L Sokol, L Kessel, R Caceres, G Gundabolu, K Tamari, R Gordon, S Mantzaris, I Jodlowski, T Yu, Y Jing, X Polineni, R Bhatia, K Pellagatti, A Boultwood, J Kambhampati, S Steidl, U Stein, C Ju, W Liu, G Kenny, P List, A Bitzer, M Verma, A |
| author_sort | Bhagat, T |
| collection | OXFORD |
| description | Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis that leads to peripheral cytopenias. We observed that SMAD7, a negative regulator of transforming growth factor-beta (TGF-β) receptor-I kinase, is markedly reduced in MDS and leads to ineffective hematopoiesis by overactivation of TGF-β signaling. To determine the cause of SMAD7 reduction in MDS, we analyzed the 3'UTR of the gene and determined that it contains a highly conserved putative binding site for microRNA-21. We observed significantly elevated levels of miR-21 in MDS marrow samples when compared with age-matched controls. miR-21 was shown to directly bind to the 3'UTR of SMAD7 and reduce its expression in hematopoietic cells. Next, we tested the role of miR-21 in regulating TGF-β signaling in a TGF-β-overexpressing transgenic mouse model that develops progressive anemia and dysplasia and thus serves as a model of human bone marrow failure. Treatment with a chemically modified miR-21 inhibitor led to significant increases in hematocrit and led to an increase in SMAD7 expression in vivo. Inhibition of miR-21 also led to an increase in erythroid colony formation from primary MDS bone marrow progenitors, demonstrating its ability in stimulating hematopoiesis in vitro. Taken together, these studies demonstrate the role of miR-21 in regulating overactivated TGF-β signaling in MDS. |
| first_indexed | 2024-03-07T06:04:01Z |
| format | Conference item |
| id | oxford-uuid:ed38634a-50db-4bcf-af5b-ffe0b81d5d81 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T06:04:01Z |
| publishDate | 2013 |
| publisher | American Society of Hematology |
| record_format | dspace |
| spelling | oxford-uuid:ed38634a-50db-4bcf-af5b-ffe0b81d5d812022-03-27T11:23:24ZmiR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling.Conference itemhttp://purl.org/coar/resource_type/c_5794uuid:ed38634a-50db-4bcf-af5b-ffe0b81d5d81Symplectic Elements at OxfordAmerican Society of Hematology2013Bhagat, TZhou, LSokol, LKessel, RCaceres, GGundabolu, KTamari, RGordon, SMantzaris, IJodlowski, TYu, YJing, XPolineni, RBhatia, KPellagatti, ABoultwood, JKambhampati, SSteidl, UStein, CJu, WLiu, GKenny, PList, ABitzer, MVerma, AMyelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis that leads to peripheral cytopenias. We observed that SMAD7, a negative regulator of transforming growth factor-beta (TGF-β) receptor-I kinase, is markedly reduced in MDS and leads to ineffective hematopoiesis by overactivation of TGF-β signaling. To determine the cause of SMAD7 reduction in MDS, we analyzed the 3'UTR of the gene and determined that it contains a highly conserved putative binding site for microRNA-21. We observed significantly elevated levels of miR-21 in MDS marrow samples when compared with age-matched controls. miR-21 was shown to directly bind to the 3'UTR of SMAD7 and reduce its expression in hematopoietic cells. Next, we tested the role of miR-21 in regulating TGF-β signaling in a TGF-β-overexpressing transgenic mouse model that develops progressive anemia and dysplasia and thus serves as a model of human bone marrow failure. Treatment with a chemically modified miR-21 inhibitor led to significant increases in hematocrit and led to an increase in SMAD7 expression in vivo. Inhibition of miR-21 also led to an increase in erythroid colony formation from primary MDS bone marrow progenitors, demonstrating its ability in stimulating hematopoiesis in vitro. Taken together, these studies demonstrate the role of miR-21 in regulating overactivated TGF-β signaling in MDS. |
| spellingShingle | Bhagat, T Zhou, L Sokol, L Kessel, R Caceres, G Gundabolu, K Tamari, R Gordon, S Mantzaris, I Jodlowski, T Yu, Y Jing, X Polineni, R Bhatia, K Pellagatti, A Boultwood, J Kambhampati, S Steidl, U Stein, C Ju, W Liu, G Kenny, P List, A Bitzer, M Verma, A miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling. |
| title | miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling. |
| title_full | miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling. |
| title_fullStr | miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling. |
| title_full_unstemmed | miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling. |
| title_short | miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling. |
| title_sort | mir 21 mediates hematopoietic suppression in mds by activating tgf β signaling |
| work_keys_str_mv | AT bhagatt mir21mediateshematopoieticsuppressioninmdsbyactivatingtgfbsignaling AT zhoul mir21mediateshematopoieticsuppressioninmdsbyactivatingtgfbsignaling AT sokoll mir21mediateshematopoieticsuppressioninmdsbyactivatingtgfbsignaling AT kesselr mir21mediateshematopoieticsuppressioninmdsbyactivatingtgfbsignaling AT caceresg mir21mediateshematopoieticsuppressioninmdsbyactivatingtgfbsignaling AT gundaboluk mir21mediateshematopoieticsuppressioninmdsbyactivatingtgfbsignaling AT tamarir mir21mediateshematopoieticsuppressioninmdsbyactivatingtgfbsignaling AT gordons mir21mediateshematopoieticsuppressioninmdsbyactivatingtgfbsignaling AT mantzarisi mir21mediateshematopoieticsuppressioninmdsbyactivatingtgfbsignaling AT jodlowskit mir21mediateshematopoieticsuppressioninmdsbyactivatingtgfbsignaling AT yuy mir21mediateshematopoieticsuppressioninmdsbyactivatingtgfbsignaling AT jingx mir21mediateshematopoieticsuppressioninmdsbyactivatingtgfbsignaling AT polinenir mir21mediateshematopoieticsuppressioninmdsbyactivatingtgfbsignaling AT bhatiak mir21mediateshematopoieticsuppressioninmdsbyactivatingtgfbsignaling AT pellagattia mir21mediateshematopoieticsuppressioninmdsbyactivatingtgfbsignaling AT boultwoodj mir21mediateshematopoieticsuppressioninmdsbyactivatingtgfbsignaling AT kambhampatis mir21mediateshematopoieticsuppressioninmdsbyactivatingtgfbsignaling AT steidlu mir21mediateshematopoieticsuppressioninmdsbyactivatingtgfbsignaling AT steinc mir21mediateshematopoieticsuppressioninmdsbyactivatingtgfbsignaling AT juw mir21mediateshematopoieticsuppressioninmdsbyactivatingtgfbsignaling AT liug mir21mediateshematopoieticsuppressioninmdsbyactivatingtgfbsignaling AT kennyp mir21mediateshematopoieticsuppressioninmdsbyactivatingtgfbsignaling AT lista mir21mediateshematopoieticsuppressioninmdsbyactivatingtgfbsignaling AT bitzerm mir21mediateshematopoieticsuppressioninmdsbyactivatingtgfbsignaling AT vermaa mir21mediateshematopoieticsuppressioninmdsbyactivatingtgfbsignaling |